首页 >
法规速递
-
Document: Minutes of the CAT meeting 19-21 February 2025-2025/4/1
2025-04-02查看详情 > -
国家药监局关于发布免于进行临床评价医疗器械目录的通告（2025年第19号）-2025/5/13
2025-05-14查看详情 > -
Page: CVMP recommendations on limited market classification and eligibility for authorisation under Article 23-2025/6/19
2025-06-20查看详情 > -
Page: Safety and residue data requirements for the establishment of maximum residue limits in minor species - Scientific guideline-2025/7/24
2025-07-25查看详情 > -
Document: Portfolio and technology meeting briefing document-2025/9/9
2025-09-10查看详情 > -
国家药监局关于修订人纤维蛋白原说明书的公告（2025年第101号）-2025/10/14
2025-10-15查看详情 > -
Document: Dates of 2026 Scientific Advice Working Party - Human (SAWP-H) meetings and submission deadlines for scientific advice, protocol assistance, qualification of novel methodologies and HTACG/EMA parallel Joint Scientific Consultation (JSC) requests
2025-11-19查看详情 > -
Page: ICH E22 General considerations for patient preference studies - Scientific guideline-2025/12/12
2025-12-15查看详情 > -
司法部、市场监管总局、国家药监局负责人就《中华人民共和国药品管理法实施条例》修订答记者问-2026/1/27
2026-01-28查看详情 > -
Document: DARWIN EU Advisory Board: Membership-2026/3/4
2026-03-05查看详情 >
